Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 19/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174049 | 0.85 | LTA4H (0.43) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2168440 | 0.82 | LTA4H (0.52) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2167587 | 0.80 | LTA4H (0.48) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2169303 | 0.80 | LTA4H (0.48) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2168820 | 0.80 | LTA4H (0.48) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2167809 | 0.80 | LTA4H (0.50) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2168432 | 0.79 | LTA4H (0.52) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2170463 | 0.78 | LTA4H (0.54) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2169343 | 0.78 | LTA4H (0.52) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL2168037 | 0.78 | LTA4H (0.52) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4726238-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | claimed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | claimed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | LTA4H 1/4885KCNH2 4064/4885EPHX2 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.